Search company, investor...

Snowdon Pharmaceuticals

snowdonpharma.com

Stage

Seed VC | Alive

Total Raised

$500K

Last Raised

$500K | 16 yrs ago

About Snowdon Pharmaceuticals

Snowdon, Inc., is a drug discovery and development company that is focused on three major therapeutic areas - cancer, acute and chronic pain and infectious diseases. In each of these therapeutic areas, Snowdon has discovered prospective drug candidates. The company employs a battery of computational tools to rapidly identify high-value molecules which can then be procured for initial biological proof of concept evaluation studies.

Headquarters Location

66 Maybury Hill Road

Princeton, New Jersey, 08540,

United States

609-577-4413

Missing: Snowdon Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Snowdon Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Snowdon Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Snowdon Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Snowdon Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Snowdon Pharmaceuticals's headquarters?

    Snowdon Pharmaceuticals's headquarters is located at 66 Maybury Hill Road, Princeton.

  • What is Snowdon Pharmaceuticals's latest funding round?

    Snowdon Pharmaceuticals's latest funding round is Seed VC.

  • How much did Snowdon Pharmaceuticals raise?

    Snowdon Pharmaceuticals raised a total of $500K.

  • Who are the investors of Snowdon Pharmaceuticals?

    Investors of Snowdon Pharmaceuticals include Foundation Venture Capital Group.

  • Who are Snowdon Pharmaceuticals's competitors?

    Competitors of Snowdon Pharmaceuticals include MerLion Pharmaceuticals, Melior Discovery, Echelon Biosciences, Prosarix, KineMed and 13 more.

Compare Snowdon Pharmaceuticals to Competitors

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

P
Pathfinder Pharmaceuticals

Pathfinder Pharma focuses on drug discovery research from invention through clinical proof of concept. They specialize in viral diseases and related cancers.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

N
Nereus Pharmaceuticals

Nereus Pharmaceuticals is a drug discovery and development company pursuing sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize biologically active compounds, the company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma. Nereus' discovery portfolio also includes additional drug candidates for oncology, infectious diseases, and inflammation.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.